Clinical Trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Protocol Amendment History 2 changes
notable Trial sites expanded: 6 -> 9 locations 2026-08-04
notable Trial sites expanded: 1 -> 5 locations 2026-03-31
Trial Details
NCT Number NCT07397338
Lead Sponsor Revolution Medicines, Inc.
Collaborators: Summit Therapeutics
Conditions Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Enrollment 370 participants
Start Date 2026-01-30
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-03